

Key Treatment Priorities


Dr Ken Romeril








Australian & NZ MRDR:
37 sites, 2600 patients
registered


New Zealand & international myeloma treatment options & pathways



New ways of evaluating and monitoring disease







**Molecular profiling
of myeloma cells**

**Treatment
A**

**Treatment
B**

Treatment C

Assessment for minimal residual disease

MRD negative

MRD positive

**Reduce treatment
intensity**

**Increase treatment
intensity**



Cyrille Touzeau and Philippe Moreau. Blood 2016 127:971-976

Myeloma registrations in 2012-2016

	Māori	Pasifika	Asian	Eur/Other	Total
<i>Total</i>					
Registrations	194	111	81	1478	1864
Crude incidence rate*	5.53	7.59	2.93	9.86	8.20
Age std incidence*	7.19	10.13	3.51	5.05	5.19

*Registrations per 100,000 population